Concentrix reports its fiscal Q3 results on September 29 carrying an ugly reminder from the prior quarter — a 10% single-day drop — into a setup where short sellers are pulling back but options traders are adding downside cover.
The most striking shift heading into this print is the retreat in short positioning. Short interest has fallen roughly 18% from early September, dropping to 13.8% of the free float — still elevated, but directionally moving against the bears. That decline arrived alongside a sharp loosening in the borrow market: availability has expanded to around 219%, up nearly 29% on the week, meaning there is now more than twice as much supply available to borrow as there are shares already shorted. Cost to borrow remains low at 0.68%, having ticked up about 18% on the week but still well within the cheap-to-borrow range. The ORTEX short score has eased to 66.5 from 69.8 two weeks ago — bears are not adding to positions ahead of the number. That picture contrasts sharply with what options positioning is signalling. The put/call ratio has jumped to 1.13, well above its 20-day average of 0.90 and roughly 1.5 standard deviations elevated. The shift is clear in the daily readings: PCR was running in the 0.58–0.86 range through mid-September before climbing above 1.10 last week. Options traders are hedging into the event even as short sellers reduce exposure.
The debate between bulls and bears is essentially a question of whether operational momentum can offset continued financial fragility. Bulls point to Q2 revenue of $2.46 billion, a modest year-on-year increase, record contract signings for the iX Suite, and strong cash flow generation, arguing the stock's value credentials — an EV/EBITDA below 5x and a PE ratio near 2.5x — make it deeply discounted relative to any reasonable recovery scenario. The mean analyst price target of $36.25 is well above the current price of $27.08, though most of the target resets happened in late June following the Q2 report, when firms including B of A Securities and Baird cut their numbers substantially. B of A trimmed its target to $26 while staying Neutral; Canaccord stayed Buy but brought its target down to $45 from $55. Bears focus on the guidance cut, the absence of share buybacks, and the ongoing margin pressure from the Webhelp integration. EPS momentum factor scores sit at the 11th and 27th percentiles on a 30- and 90-day basis — estimates continue to drift lower, not higher.
The ownership picture adds texture. Two 13D filers are on the register — Impactive Capital and Groupe Bruxelles Lambert — making this a stock with confirmed activist interest. Groupe Bruxelles Lambert has already moved, offloading 6 million shares in April at $22.25 and cutting its stake from 14.24% to 4.55% as last disclosed. Impactive Capital reported 4.9% as of November 2025. These are event-driven disclosures around the 5% threshold; stakes are as last disclosed and holders dropping below 5% may not file again. The CEO, Christopher Caldwell, made a small open-market purchase of 1,000 shares at $21.25 in July — a modest signal of conviction at lower prices, though not material in dollar terms. BlackRock and Fidelity have both been adding, with BlackRock growing its stake substantially to roughly 11% as of August.
The September 29 print will test whether the operational trajectory Concentrix described in Q2 — modest revenue growth, improving cash flow, restructuring progress — can survive the ongoing drag from weakening EPS estimates and client shift headwinds well enough to interrupt what has now become a two-quarter streak of double-digit negative post-earnings reactions.
See the live data behind this article on ORTEX.
Open CNXC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
